Calquence savings card: as little as $0 a month with commercial insurance

How to pay the least

Ask for the cash price

Calquence

We didn’t find one.

Ask your pharmacy for Calquence’s cash price, and one or two other pharmacies too.
Calquence’s savings card works only with insurance from a job or one you bought.

Free from the maker, if you qualify AZ&Me Prescription Savings Program. For AZ&Me’s Specialty and Primary products, your annual adjusted gross income must be at or below 300% of the Federal Poverty Level Or call 1-800-292-6363.

See if you qualify

Compare every option

Brand nameCalquence

Authorized genericacalabrutinib

Regular genericacalabrutinib

What you’d pay

Cash priceAsk the pharmacy

Not soldThere isn’t one

Not soldNone found

Same as Calquence?

The original

–

Brand nameThe maker’s card

CALQUENCE Co-pay Savings Program (AstraZeneca Access 360)

Savings card from AstraZeneca

No insuranceNeeds insuranceNo cash price listed.

Insurance · as little as $0 a month

Or call 1-844-275-2360.

In the maker’s words

“Eligible patients may pay as little as $0 per month for CALQUENCE.”

From the maker’s offer on myaccess360.com, checked October 27, 2026. Co-pay cards can’t be used with Medicare (including Medicare Advantage), Medicaid, TRICARE or VA.

Maker’s card or discount card?

A discount card like GoodRx lowers the pharmacy’s cash price, but for a brand-name drug that price often stays high. Compare it with the maker’s card above. You can usually use one or the other on a fill, not both.

Authorized genericNot sold

There isn’t one. An authorized generic is Calquence itself, from the same company, sold without the brand name, and usually for less. For now Calquence is the only choice; its maker’s savings card can lower what you pay.

See the brand name →

Regular genericNot sold

We didn’t find one. Generics usually come once the brand’s patents and exclusivity end. Until then, the maker’s savings card is the way to pay less.

See the brand name →

What it’s used for

What the FDA label says

CALQUENCE is a kinase inhibitor indicated:

In combination with bendamustine and rituximab for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL) who are ineligible for autologous hematopoietic stem cell transplantation (HSCT).
For the treatment of adult patients with MCL who have received at least one prior therapy.
For the treatment of adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).

Source: the FDA label for Calquence (AstraZeneca Pharmaceuticals LP), February 19, 2026. Full label on DailyMed

Good to know

“Commercial insurance” means a plan from a job, from the marketplace, or one you buy yourself. A retiree plan that’s part of Medicare counts as Medicare. Co-pay cards can’t be used with Medicare (including Medicare Advantage), Medicaid, TRICARE or VA.
Most cards need a sign-up on the maker’s site, and many work only if your plan covers the drug. Then give the card’s details to your pharmacy.
Don’t stop or change a medicine without talking to your pharmacist or prescriber.

Prices checked October 27, 2026. Prices change: confirm with the pharmacy before you fill. drugalt.com/drug/calquence/